Pipeline
Traverse Biotech has a growing pipeline of cutting-edge immunotherapies with the potential to treat some of the most challenging diseases. We are developing these highly differentiated products that are derived from clinically validated therapeutic platforms.
Research &
Development
Development
Preclinical
IND-enabling
Phase I/II
Partner
TB–Bs1
TB–NOD–2
TB–UA–1
R&D
More on the Science behind our Lead Product
ROR2 as a T Cell Engager Target
ROR2 is an attractive novel target linked to tumor-dependent pathways and processes
Expressed during embryonic development.
Reappears during cancer development
Activates multiple pro-tumor pathways
Relevant publications on ROR2:
Read more about the Duobody® platform here.